Dale Tavris

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. doi request reprint Gender differences in the treatment of non-ST-segment elevation myocardial infarction
    Dale Tavris
    Food and Drug Administration, Center for Devices and Radiological Health, Division of Epidemiology, USA
    Clin Cardiol 33:99-103. 2010
  2. doi request reprint Long-term outcomes after transmyocardial revascularization
    Dale R Tavris
    US Food and Drug Administration, Center for Devices and Radiological Health, Division of Epidemiology, Silver Spring, Maryland Electronic address
    Ann Thorac Surg 94:1500-8. 2012
  3. ncbi request reprint Bleeding and vascular complications at the femoral access site following percutaneous coronary intervention (PCI): an evaluation of hemostasis strategies
    Dale R Tavris
    US Food and Drug Administration FDA, Silver Spring, MD, USA
    J Invasive Cardiol 24:328-34. 2012

Detail Information

Publications3

  1. doi request reprint Gender differences in the treatment of non-ST-segment elevation myocardial infarction
    Dale Tavris
    Food and Drug Administration, Center for Devices and Radiological Health, Division of Epidemiology, USA
    Clin Cardiol 33:99-103. 2010
    ..One explanation may be that they tend to be treated less aggressively than men even when more aggressive treatment is warranted. The purpose of this analysis was to assess this issue...
  2. doi request reprint Long-term outcomes after transmyocardial revascularization
    Dale R Tavris
    US Food and Drug Administration, Center for Devices and Radiological Health, Division of Epidemiology, Silver Spring, Maryland Electronic address
    Ann Thorac Surg 94:1500-8. 2012
    ....
  3. ncbi request reprint Bleeding and vascular complications at the femoral access site following percutaneous coronary intervention (PCI): an evaluation of hemostasis strategies
    Dale R Tavris
    US Food and Drug Administration FDA, Silver Spring, MD, USA
    J Invasive Cardiol 24:328-34. 2012
    ..Since that time, several more VCDs have been approved by the Food and Drug Administration (FDA). This research evaluates the safety profiles of current frequently used VCDs and other hemostasis strategies...